




Looking ahead, sales trajectories




Worldwide prescription drug sales are projected to have a positive CAGR of **6.9%** between 2019-24 with sales expected to reach **US\$1.18 trillion**.

Drivers of growth are expected to be:



-  Accelerated drug approvals
-  Increased potential for an additional US\$109 billion from orphan drug sales
-  Amplified sales from oncology therapies



Oncology is expected to have almost a 20% share of the worldwide market by 2024 and a 11.4% in CAGR growth.



In 2018, 53% were **biotech** products as compared with 34% in 2010.



Worldwide orphan drug sales are expected to have double the CAGR of non-orphan drugs, at 12.3% over the 2019–24 period.



Global medical devices market was valued at US\$425.5 billion in 2018 and is expected to reach US\$612.7 billion by 2025.

Emerging markets focus on domestic medtech companies—e.g., China wants domestically produced medical devices to account for half the medical devices used by hospitals in 2020, and by 2025, that number is expected to rise to 70 percent.

Why do medtech companies need to implement cost-reduction strategies and remain competitive?

- Increased market entry of non-traditional players such as tech giants.
- Downstream pricing pressures
- Stringent regulations
- Operational inefficiencies



▶ Learn more at www.deloitte.com/lifesciencesoutlook

Deloitte.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see www.deloitte.com/about for a more detailed description of DTTL and its member firms. Deloitte provides audit, consulting, financial advisory, risk management, tax and related services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries and territories, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte’s more than 200,000 professionals are committed to becoming the standard of excellence.

Disclaimer

This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the “Deloitte Network”) is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this publication.

About Life Sciences and Health Care at Deloitte Touche Tohmatsu Limited

The Deloitte Touche Tohmatsu Limited’s life sciences and health care (LSHC) industry group is composed of more than 12,000 professionals in more than 90 countries. These member firm professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information about the DTTL LSHC industry group, email dttlshc@deloitte.com or access www.deloitte.com/healthcare.
©2020. For more information, contact Deloitte Touche Tohmatsu Limited.